TL;DR
An extended analysis argues that lifetime exposure to circulating LDL particles is the primary cause of atherosclerotic cardiovascular disease and that modern lipid-lowering drugs can reduce LDL to non-pathogenic levels. The piece contends genetic, clinical, and mechanistic evidence supports aggressive, early pharmacological prevention and that very low LDL is safe.
What happened
A long-form article presents a step-by-step case that cardiovascular disease (CVD) can be eliminated by targeting circulating low-density lipoproteins (LDLs). Drawing on biochemical, epidemiological and genetic lines of evidence, the author describes how retention of apoB-containing lipoproteins — and to a lesser extent apoB bound to apolipoprotein(a), Lp(a) — in the arterial wall initiates inflammation and plaque formation. The piece distinguishes measurement types (LDL-C versus apoB counts), emphasizes that circulating lipoprotein levels are largely determined by genetics, and traces therapeutic advances from statins to modern biologics such as PCSK9 inhibitors. The author argues that pharmacological reduction of LDL to very low levels is achievable, empirically safe according to trials and genetic studies, and that preventative use in otherwise healthy young adults could eliminate future CVD risk. The article concludes that, given these points, cardiovascular disease is effectively a solved problem.
Why it matters
- If circulating LDL is the root cause of atherosclerosis, interventions that substantially lower LDL could prevent most CVD events.
- Wider acceptance of this view would shift clinical practice toward earlier, potentially lifelong, pharmacologic prevention rather than later-stage treatment.
- Differences in how LDL is measured (LDL-C vs. apoB or Lp(a)) could influence risk assessment and treatment decisions.
- Claims about the safety of very low LDL levels, if borne out, would remove a major barrier to aggressive lipid lowering.
Key facts
- The article states cardiovascular disease is the leading cause of death in developed countries.
- It identifies retention of apoB-containing lipoproteins in the arterial wall as the initiating event in atherosclerosis.
- ApoB-only LDLs are described as the primary pathogenic particles; apoB bound to Lp(a) is a secondary contributor.
- LDL measurements are distinct: LDL-C is an estimated mass-based lab value, while apoB and Lp(a) measure specific particle types or counts.
- The author cites genetic evidence and epidemiology to support a causal link between circulating LDL and CVD.
- Pharmacological tools from statins to PCSK9-targeting biologics are presented as capable of dramatically lowering LDL.
- The article asserts trials and genetic data indicate very low LDL levels are safe and provide ongoing benefit.
- It argues that circulating lipoprotein concentrations are largely genetically determined with limited lifestyle impact.
- The author recommends preventative LDL-lowering therapy for healthy young adults to eliminate future risk, per their analysis.
What to watch next
- Whether professional societies or public-health agencies update guidelines to endorse routine early preventive LDL-lowering — not confirmed in the source.
- Long-term, population-level outcomes if aggressive LDL-lowering strategies are broadly adopted — not confirmed in the source.
- Further randomized trial data or post-market surveillance addressing very long-term non-cardiovascular effects of maintaining extremely low LDL — not confirmed in the source.
Quick glossary
- LDL: Low-density lipoprotein, a class of particles that transport cholesterol and triglycerides in the blood; associated with atherosclerotic plaque formation when retained in arterial walls.
- apoB: Apolipoprotein B, a protein component attached to certain lipoproteins; each atherogenic particle typically carries one apoB molecule, making apoB a marker for particle number.
- Lp(a): Lipoprotein(a), an LDL-like particle in which apoB is bound to apolipoprotein(a); it is considered a separate, genetically determined risk factor for cardiovascular disease.
- LDL-C: An estimated laboratory measure of the cholesterol mass carried within LDL particles, typically reported in mg/dL and distinct from direct particle counts like apoB.
- PCSK9 inhibitors: A class of drugs (including monoclonal antibodies and other biologics) that lower LDL by blocking the PCSK9 protein, which regulates LDL receptor levels on liver cells.
Reader FAQ
Does the article conclude cardiovascular disease is truly solved?
Yes — the author argues that targeting circulating LDL makes CVD effectively solvable, based on genetic, mechanistic and clinical evidence presented in the piece.
Are LDL-lowering treatments safe at very low LDL levels?
The article states clinical trials and genetic studies indicate achieving very low LDL is empirically safe.
Should healthy young adults take LDL-lowering drugs to prevent future CVD?
The author recommends preventative therapy for young adults in good health, arguing it would eliminate future risk; this is the article's position, not a universally confirmed guideline.
Do lifestyle factors strongly determine circulating LDL levels?
The article claims circulating lipoprotein levels are largely genetically determined with only minimal influence from lifestyle.
totalhealth on Concerns about the legitimacy and integrity of Nucleus Genomics November 26, 2025 Well, when half the article is about them plagiarizing Herasight, and when the only source of…
Sources
- Cardiovascular disease is a solved problem
- A plant-based diet and coronary artery disease: a mandate for …
- Heart disease remains leading cause of death as key …
- Cardiovascular disease and a Solution
Related posts
- C3: An Ergonomic, Safe and Familiar Evolution of the C Language
- Readers seek concise, expository textbooks that survey modern physics
- When Ctrl-C Outperforms a Profiler: Practical Sampling with a Debugger